Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Adamas Pharmaceuticals Inc | adms10k2020ex321.htm |
| 10-K - 10-K - Adamas Pharmaceuticals Inc | adms-20201231.htm |
| EX-31.2 - EX-31.2 - Adamas Pharmaceuticals Inc | adms10k2020ex312.htm |
| EX-31.1 - EX-31.1 - Adamas Pharmaceuticals Inc | adms10k2020ex311.htm |
| EX-21.1 - EX-21.1 - Adamas Pharmaceuticals Inc | adms10k2020ex211.htm |
| EX-10.31 - EX-10.31 - Adamas Pharmaceuticals Inc | adms10k2020ex1031.htm |
| EX-10.22 - EX-10.22 - Adamas Pharmaceuticals Inc | adms10k2020ex1022.htm |
| EX-10.19 - EX-10.19 - Adamas Pharmaceuticals Inc | adms10k2020ex1019.htm |
| EX-10.6 - EX-10.6 - Adamas Pharmaceuticals Inc | adms10k2020ex106.htm |
| EX-2.1 - EX-2.1 - Adamas Pharmaceuticals Inc | adms10k2020ex21.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-234570) and Form S-8 (Nos. 333-249872, 333-236619, 333-230058, 333-223147, 333-216313, 333-210255, 333-202467 and 333-195384) of Adamas Pharmaceuticals, Inc. of our report dated February 23, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
February 23, 2021